HC Wainwright Reaffirms Buy Rating for NextCure (NASDAQ:NXTC)

HC Wainwright reissued their buy rating on shares of NextCure (NASDAQ:NXTC) in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock, down from their previous target price of $4.00. HC Wainwright also issued estimates for NextCure’s FY2029 earnings at ($0.55) EPS.

NextCure Price Performance

Shares of NASDAQ NXTC opened at $0.75 on Friday. The stock has a market capitalization of $21.01 million, a price-to-earnings ratio of -0.36 and a beta of 0.71. The business has a 50-day moving average of $0.78 and a 200-day moving average of $1.12. NextCure has a fifty-two week low of $0.66 and a fifty-two week high of $2.57.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07). On average, sell-side analysts expect that NextCure will post -1.87 EPS for the current year.

Hedge Funds Weigh In On NextCure

Hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC grew its holdings in shares of NextCure by 40.6% in the 4th quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock valued at $61,000 after acquiring an additional 22,724 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of NextCure by 14.2% in the 3rd quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock valued at $307,000 after acquiring an additional 27,812 shares in the last quarter. Peapod Lane Capital LLC bought a new position in shares of NextCure in the 4th quarter valued at about $311,000. Renaissance Technologies LLC grew its holdings in NextCure by 27.9% during the fourth quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock worth $400,000 after purchasing an additional 113,300 shares during the period. Finally, Tang Capital Management LLC grew its holdings in NextCure by 7.3% during the fourth quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock worth $540,000 after purchasing an additional 47,614 shares during the period. Institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.